Actimmune® is indicated for chronic granulomatous disease (CGD) and severe, malignant osteopetrosis

Our development programs are focused in the areas of pulmonology and hepatology.

View Development Pipeline

	March 9, 2010 FDA Advisory Committee Recommends Approval of InterMune's Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis March 9, 2010 InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
	View All Press Releases

	March 9, 2010 Webcast - InterMune Inc. Conference Call to Discuss Outcome of FDA Advisory Committee
	View Our Event Calendar